Arcoris Bio, a Swiss life science company based in Schlieren, has raised €6.7 million (CHF 6.3 million) in an oversubscribed seed round to advance development and commercialization of its MUSE biomarker detection platform. The financing was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and a group of new and existing private investors.
Founded in 2022 by scientists Simon Restrepo and Scott E. Fraser alongside entrepreneur H. Kaspar Binz, Arcoris Bio develops advanced tools for research and diagnostics, with a focus on multiplex imaging and digital pathology. The company’s flagship technology, MUSE (Multiplex Universal Signal Enhancement), enables highly sensitive, simultaneous detection of multiple biomarkers and is designed to offer universal, programmable signal amplification across modalities.
Leadership framed the round as a major inflection point for scaling and market readiness. CEO Matyas Vegh said the funding will accelerate getting innovations to market, strengthen operations, and help meet growing industry demand. Co-founder and CSO Simon Restrepo emphasized that bringing on two lead investors with deep industry expertise validates the company’s technical strategy and mission to transform biomarker detection and digital pathology.
According to the company and investors, MUSE aims to address a critical gap in biomarker detection by enhancing performance of existing imaging and diagnostic systems while simplifying workflows. The platform is described as delivering high sensitivity and ease of use, enabling measurement of several hard-to-detect biomarkers within a single sample at higher throughput—key for applications in precision medicine, complex disease classification, and spatial multiomics.
Investors highlighted the potential impact across research and clinical settings. Ventura Ace noted early traction with industry partners and characterized MUSE as an enabling technology for digital pathology. ZEISS Ventures described MUSE’s broad applicability as akin to a “molecular GPU,” amplifying the capabilities of current biomarker platforms and opening new paths for innovation in diagnostics, drug discovery, and translational research.
Proceeds from the seed round will be used to industrialize the MUSE platform, expand strategic partnerships, and accelerate new product launches. The company plans to scale manufacturing and commercial operations while deepening collaborations that integrate MUSE into high-throughput, data-rich workflows used by researchers and clinicians.
Arcoris Bio positions itself within a broader European push to industrialize next-generation biomarker and diagnostic technologies. With strong venture backing and a platform built for multiplex sensitivity and operational simplicity, the company aims to support the shift toward more precise, data-driven diagnostics and to play a foundational role in the evolution of digital pathology and spatial biology.
Arcoris Bio
Biomarker detection platform
Arcoris Bio
Biomarker detection platform
WeWillWrite, an Oslo-based edtech and AI startup, has raised €2 million in growth funding to expand its collaborative writing platform and strengthen operations ahead of a broader global rollout. The round was co-led by Skyfall Ventures and Spintop Ventures, with continued participation from Kahoot! co-founders Johan Brand and Jamie Brooker, alongside angels Aurora Klæboe Berg, Gaute Godager, Fredrik Schjold, and Alexander Lund. Founded in 2019 by Daniel Senn, Johannes Stensen, and Erlend Klouman Høiner, the company focuses on process‑oriented writing instruction that treats writing as a social and creative activity rather than a solitary task.
The platform enables students to write short texts, exchange peer feedback, and build confidence through guided, collaborative exercises in a shared classroom environment. Drawing on Scandinavian pedagogy, WeWillWrite emphasizes participation, mastery, and iterative improvement. According to the company, the product is already used by millions of students and over 100,000 teachers across North America. With the new investment, WeWillWrite plans to reinforce its Norwegian operations, expand in key U.S. regions, and prepare for a global rollout in 2026–27. Funds will support team growth and continued product development, including tools to enhance classroom engagement and teacher support.
WeWillWrite positions its approach as complementary to the growing presence of AI in education, focusing on student-generated writing and peer interaction. The company’s design centers on short, structured writing tasks that promote feedback, reflection, and incremental skill-building. The goal is to help students develop authentic writing skills and confidence while providing teachers with a practical framework to run collaborative writing sessions. The platform’s format is oriented toward classroom feasibility: brief activities, clear prompts, and mechanisms for peer review that fit within standard lesson times.
The investor group highlighted the company’s combination of pedagogy and technology as a driver of adoption. Skyfall Ventures underscored the founding team’s domain expertise and early traction in the U.S. market. Spintop Ventures noted the presence of network effects within teacher communities, viewing engagement among educators as a key indicator of scalability. Returning backers, including the Kahoot! co-founders, pointed to the platform’s classroom impact and its potential to foster a sustained, positive relationship with writing among students.
Proceeds will be allocated to scaling product capabilities, expanding implementation support for schools, and growing the organization to meet rising demand. The company plans to invest in features that improve teacher workflows and facilitate peer feedback at scale, while maintaining a focus on student agency and classroom fit. WeWillWrite also intends to deepen market operations in Norway as a base for continued European development, while prioritizing expansion in U.S. regions where adoption is already established.
WeWillWrite is part of a growing group of Norwegian edtech companies attracting interest from cross‑border investors. Its model aims to address persistent challenges in writing instruction by making the process collaborative and engaging, with an explicit focus on building confidence and competence. With new funding, the company seeks to broaden its footprint, refine its product for diverse classroom contexts, and support teachers with structured tools that emphasize student writing, peer interaction, and measurable progress. The stated objective is to scale a platform that helps students practice writing consistently and meaningfully, while providing educators with a practical, repeatable framework for classroom implementation.
